pembrolizumab,lenvatinib
eisai,merck
['lenva', 'pembro', 'rcc,(-irccs),(-srcc),(-urcc)']
lenvatinib and pembrolizumab has activity in non-clear cell rcc. no randomised data makes patients characteristics relevant ( good risk here). i think many will adopt this as standard of care but without randomisation it s hard to tell the extent of the benefit. #asco23 
Interested in Urology Cancers, biomarkers and drug development.